Comparative Pharmacology
Head-to-head clinical analysis: KELNOR versus NORLESTRIN FE 2 5 50.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KELNOR versus NORLESTRIN FE 2 5 50.
KELNOR vs NORLESTRIN FE 2.5/50
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combined oral contraceptive; inhibits ovulation by suppressing gonadotropin release (FSH and LH) primarily via progestational activity; increases viscosity of cervical mucus to inhibit sperm penetration; alters endometrium.
Combination oral contraceptive containing norethindrone (progestin) and ethinyl estradiol (estrogen). Inhibits ovulation by suppressing gonadotropin-releasing hormone (GnRH) via negative feedback on the hypothalamus and pituitary. Increases cervical mucus viscosity to impede sperm penetration and induces endometrial atrophy to prevent implantation.
KELNOR (norethindrone acetate and ethinyl estradiol) is a combined oral contraceptive. Typical adult dose: 1 tablet (norethindrone acetate 1 mg/ethinyl estradiol 20 mcg) orally once daily for 21 days, followed by 7 placebo tablets, starting on day 1 of menstrual cycle.
One tablet orally once daily, each containing 2.5 mg norethindrone acetate and 50 mcg ethinyl estradiol, plus 7 iron tablets (75 mg ferrous fumarate) taken during the placebo week.
None Documented
None Documented
Terminal elimination half-life 12-15 hours; clinically relevant for once-daily dosing.
Norethindrone: ~8-10 hours (terminal), requiring daily dosing for stable contraceptive effect. Ethinyl estradiol: ~13-21 hours (terminal), supporting once-daily administration.
Primarily renal excretion of unchanged drug (70-80%) and glucuronide conjugate (10-15%); biliary/fecal elimination accounts for <5%.
Norethindrone: ~80% renal (as glucuronide and sulfate conjugates), ~20% fecal. Ethinyl estradiol: ~40% renal, ~60% fecal, with enterohepatic recirculation.
Category C
Category C
Oral Contraceptive
Oral Contraceptive